Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $9.7250 (14.75%) ($9.7250 - $9.7250) on Sun. Jan. 30, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 8.29% (three month average) | RSI | 25 | Latest Price | $9.7250(14.75%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -5.9% a day on average for past five trading days. | Weekly Trend | TGTX declines -14.2% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) (0%) (0%) (0%) (0%) (0%) | Factors Impacting TGTX price | TGTX will decline at least -4.145% in a week (0% probabilities). (0%) (0%) (0%) (0%) (0%) | | | | | Relative Volatility | | | | Market Trend Strength | -4.145% (StdDev 8.29%) | Hourly BBV | 0 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-19.25(-297.94%) | Resistance Level | $15.35 | 5 Day Moving Average | $12.27(-20.74%) | 10 Day Moving Average | $13.2(-26.33%) | 20 Day Moving Average | $15.35(-36.64%) | To recent high | -72.7% | To recent low | 14.7% | Market Cap | $N/A | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |